BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

INX-189: Additional Phase Ib data

Inhibitex also plans to expand a Phase II trial of INX-189 in patients with chronic HCV genotype 2 and 3 infection to include additional cohorts evaluating once-daily 100 and 200 mg INX-189 in combination with ribavirin for 12 weeks. The Phase II trial, which began in August, is evaluating once-daily 25, 50 and 100 mg INX-189 in combination with peginterferon alfa-2a and ribavirin for 12 weeks.

Inhibitex previously reported data from a separate Phase Ib trial in 67 evaluable treatment-naïve patients...

Read the full 388 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >